EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors

Svit Ferjančič Benetik, Matic Proj iD, Damijan Knez iD, Urban Košak, Anže Meden iD, Katja Krajšek, Anja Pišlar, Selena Horvat, Urban Švajger, Nataša Tešić, Lenka Pulkrabkova, Ondrej Soukup iD und 16 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c00933 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Svit Ferjančič Benetik und 27 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Ljubljana, 1000 Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Butyrylcholinesterase, Cholinesterase Inhibitors, Cognitive Dysfunction, Mitogen-Activated Protein Kinase 14. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Grantová Agentura Ceské Republiky, Narodowe Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The currently approved drugs for the treatment of Alzheimer’s disease (AD) fail to address its interconnected pathological processes. Inhibition of butyrylcholinesterase (BChE) and p38α mitogen-activated protein kinase (p38α MAPK) offers an innovative dual approach to mitigate two major drivers of neurodegeneration in AD: cholinergic deficit and neuroinflammation. Using structure-based drug design and a library of known p38α MAPK inhibitors, we developed first-in-class, selective dual BChE/p38α MAPK inhibitors with balanced activity against both targets. The X-ray crystal structures of the two most promising molecules bound to both enzymes were solved. Those ligands effectively reduced the production of proinflammatory markers in vitro and ex vivo in phytohemagglutinin/lipopolysaccharide neuroinflammation models. Remarkably, these compounds also significantly improved cognition in scopolamine- and lipopolysaccharide-induced models of cognitive dysfunction in mice. Because our dual-acting inhibitors target both the symptoms and the underlying neuropathology, they offer an innovative and comprehensive strategy to combat AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ButyrylcholinesteraseCholinesterase InhibitorsCognitive DysfunctionMitogen-Activated Protein Kinase 14Neuroinflammatory DiseasesProtein Kinase InhibitorsAnimalsHumansMaleMiceAlzheimer DiseaseCrystallography, X-RayLipopolysaccharidesModels, MolecularStructure-Activity Relationship

Substanzen

ButyrylcholinesteraseCholinesterase InhibitorsLipopolysaccharidesMitogen-Activated Protein Kinase 14Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Faculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Ljubljana, 1000 Ljubljana, Slovenia.
  • Department for Therapeutic Services, Blood Transfusion Center of Slovenia, 1000 Ljubljana, Slovenia.
  • Biomedical Research Centre, University Hospital in Hradec Kralove, 500 05 Hradec Kralove, Czech Republic.
  • Faculty of Science, Department of Chemistry, University of Hradec Kralove, 500 03 Hradec Kralove, Czech Republic.
  • Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, 91220 Paris, France.
  • Department of Pharmacodynamics, Chair of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Krakow, Poland.

ORCID-Profile: Matic Proj, Damijan Knez, Anže Meden, Ondrej Soukup, Florian Nachon, Jose Dias, Stanislav Gobec

Förderung

  • NIA NIH HHS
  • Grantová Agentura Ceské Republiky
  • Narodowe Centrum Nauki
  • The Slovenian Research and Innovation Agency
  • Ministère des Armées
  • NIH

Zitieren

APA

Ferjančič Benetik, S., Proj, M., Knez, D., Košak, U., Meden, A., Krajšek, K., Pišlar, A., Horvat, S., Švajger, U., Tešić, N., Pulkrabkova, L., Soukup, O., Skarka, A., Andrys, R., Brazzolotto, X., Igert, A., Nachon, F., Dias, J., Detka, J., …, & Gobec, S. (2025). Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00933

Vancouver

Ferjančič Benetik S, Proj M, Knez D, Košak U, Meden A, Krajšek K, et al. Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00933

BibTeX
@article{FerjaniBenetik2025,
  author = {Ferjančič Benetik, Svit and Proj, Matic and Knez, Damijan and Košak, Urban and Meden, Anže and Krajšek, Katja and Pišlar, Anja and Horvat, Selena and Švajger, Urban and Tešić, Nataša and Pulkrabkova, Lenka and Soukup, Ondrej and Skarka, Adam and Andrys, Rudolf and Brazzolotto, Xavier and Igert, Alexandre and Nachon, Florian and Dias, Jose and Detka, Jan and Gdula-Argasińska, Joanna and Wyska, Elżbieta and Szafarz, Małgorzata and Manik, Aleksandra and Płachtij, Natalia and Musílek, Kamil and Sałat, Kinga and Obreza, Aleš and Gobec, Stanislav},
  title = {Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c00933}
}
Kostenlos starten →